Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alkermes' Depression Drug Likely Needs Another Trial After Crushing US Advisory Cmte. Vote

Nov 02 2018

• By Michael Cipriano

Brain decline and dementia or aging as memory loss concept for brain cancer decay or an Alzheimer's disease with old rusting mechanical gears and cog wheels in the shape of a human head with rust.

Related Content

Refusal Reversal: Alkermes Review Back On Track, But Could Still Be Bumpy

Apr 17 2018

Alkermes Depression Drug Faces Tough Questions At US FDA Advisory Committee

Oct 30 2018

Related Companies

Alkermes plc

Additional Topics

United States Advisory Committees Drug Review Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window